Weight Loss Investigational 🔥 Trending

Eloralintide

A selective amylin receptor agonist from Eli Lilly that has moved into Phase 3 obesity trials.

AmylinObesityPhase 3InvestigationalEli Lilly

Also referenced as: LY3841136

Also appears in: Hormone

Status
Investigational

This compound has a genuine development or study trail, but it is not an approved routine drug.

Category
Weight Loss

Primary lane: Weight Loss. Also surfaces under Hormone for browsing and discovery.

Aliases
1

LY3841136

Signal depth
Medium

No FDA label signal · 18 trials · 6 PubMed results

Promising
Research evidence

Eloralintide has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

Eloralintide has 17 name-matched clinical trials (highest phase: Phase 3) and 6 PubMed-indexed publications and is not FDA-approved. 1 trial has posted results.

Human data
Phase 3
Trial quality
Large RCT
Outcomes
Clinical outcomes
Replication
Meta-analysis
Literature
Emerging
PHASE3 · Randomized A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes PHASE3 · Randomized Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight The Lancet · 27 citations Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial Molecular Metabolism · 14 citations Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept Diabetes · 3 citations 882-P: Eloralintide, a Selective, Long-Acting Amylin Receptor Agonist for Obesity—Phase 1 Proof of Concept Journal Article Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What eloralintide is

Eloralintide is Eli Lilly’s investigational selective amylin receptor agonist for obesity and overweight.

Why it matters

It gives the library a major amylin-only obesity candidate, which helps separate it from dual-pathway agents like amycretin or petrelintide combination narratives. The fact that it has already advanced into Phase 3 makes it much more than a speculative name.

Regulatory context

Eloralintide is not FDA approved. It sits firmly in the late-stage investigational category.

Practical reading note

This is one of the better examples of why not every important obesity peptide is another GLP-1 story. Amylin-focused drugs are now a real lane of their own.